Integrated drug product development - from lead candidate selection to life-cycle management

The Process of New Drug Discovery and Development, Second Edition

Volumn , Issue , 2006, Pages 15-54

  Pudipeddi, Madhu ^a   Serajuddin, Abu T M ^b   Mufson, Daniel ^c  

^a Novartis Pharmaceuticals Corporation   (India)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Apotherx LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85031271393     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (123)

1. Lemberger, A.P., Higuchi T., Busse, L.W., Swintowsky, J.V., and Wurster, D.E., Preparation of some steroids in microcrystalline form by rapid freeze-sublimation technique, J. Am. Pharm. Assoc., 43, 338, 1954.
2. Nelson, E. and Schaldemose, I., Urinary excretion for evaluation of drug absorption I, J. Am. Pharm. Assoc., 48, 489, 1959.
3. Levy, G. and Nelson, E., Pharmaceutical formulation and therapeutic efficacy, JAMA, 177, 689, 1961.
4. Gibaldi, M. and Kanig, J.L., Absorption of drugs through the oral mucosa, J. Oral. Ther. Pharmacol., 31, 440, 1963.
5. Wagner, J.G., Biopharmaceutics: absorption aspects, J. Pharm. Sci., 50, 359, 1961.
6. Liberman, S.V., Kraus, S.R., Murray, J., and Wood, J.H., Aspirin formulation and absorption rate I. Criteria for serum measurements with human panels, J. Pharm. Sci., 53, 1486, 1964.
7. Kaplan, S.A., Biopharmaceutical considerations in drug formulation design and evaluation, Drug Metab. Rev., 1, 15, 1972.
8. Yalkowsky, S.H. and Rubino, J.T., Solubilization by cosolvents Part 1, J. Pharm. Sci., 74, 416, 1985.
9. Serajuddin, A.T., Solid dispersion of poorly water soluble drugs: early promises, subsequent problems, and recent breakthroughs, J. Pharm. Sci., 88, 1058, 1999.
10. Lieberman, H.A., Lachman, L., and Schwartz, J.B., Eds., Pharmaceutical Dosage Forms: Tablets, Vols. I-III, Marcel Dekker, New York, 1990.
11. Gibson, M., Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Selection to Commercial Dosage Form, CRC Press LLC, Leicestershire, 2004.
12. Venkatesh, S. and Lipper, R.A., Role of the development scientist in compound lead selection and optimization, J. Pharm. Sci., 89, 145, 2000.
13. Drews, J., Drug discovery: a historical perspective, Science, 287, 1960, 2000.
14. Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Delivery Rev., 23, 3, 1997.
15. Prentis, R.A., Lis, Y., and Walker, S.R., Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985), Br. J. Clin. Pharmacol., 25, 387, 1988.
16. Kerns, E.H. and Li, D., Pharmaceutical profiling in drug discovery, Drug Disc. Today, 8, 316, 2003.
17. Ho, N.F.H., Raub, T.J., Burton, P.S., Barsuhn C.L., Adson, A., Audus, K.L., and Borchardt, R.T., Quantitative approaches to delineate passive transport mechanisms in cell culture monolayers, in Transport Processes in Pharmaceutical Systems, Amidon, G.L., Lee, P.I., and Topp, E.M., Eds., Marcel Dekker, New York, 2000, p. 219.
18. Clark, D.E., Computational methods for the prediction of ADME and toxicity, Adv. Drug Delivery Rev., 54, 253, 2002.
19. Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W., and Kopple, K.D., Molecular properties that influence oral absorption of drug candidates, J. Med. Chem., 45, 2615, 2002.
20. Yalkowsky, S.H. and Valvani, S.C., Solubility and partitioning I: solubility of nonelectrolytes in water, J. Pharm. Sci., 69, 912, 1980.
21. Klopman, G., Wang, S., and Balthasar, D.M., Estimation of aqueous solubility of organic molecules by the group contribution approach. Application to the study of biodegradation, J. Chem. Inf. Comput. Sci., 32, 474, 1992.
22. Huuskonen, J., Salo, M., and Taskinen, J., Aqueous solubility prediction of drugs based on molecular topology and neural network modeling, J. Chem. Inf. Comput. Sci., 38, 450, 1998.
23. Chen, X.-Q., Cho, S.J., Li, Y., and Venkatesh, S., Prediction of aqueous solubility of organic compounds using a quantitative structure-property relationship, J. Pharm. Sci., 91, 1838, 2002.
24. McKenna, J.M., Halley, F., Souness, J.E., McLay, I.M., Pickett, S.D., Collis, A.J., Page, K., and Ahmed, I., An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors, J. Med. Chem, 45, 2173, 2002.
25. Kenseth, J.R. and Coldiron, S.J., High throughput characterization and quality control of small molecule combinatorial libraries, Curr. Opin. Chem. Biol, 8, 418, 2004.
26. Faller, B., Improving solubility in lead optimization, Am. Pharm. Rev., 7, 30, 2004.
27. Serajuddin, A.T.M. and Pudipeddi, M., Salt selection strategies, in Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Stahl, P.H. and Wermuth, C.G., Eds., Wiley-VCH, Weinheim, 2002, p. 135.
28. Hilal, S.H., El-Shabrawy, Y., Carreira, L.A., Karickhoff, L.W., Toubar, S.S., and Rizk, M., Estimation of ionization pKa of pharmaceutical compounds using the computer program SPARC, Talanta, 43, 607, 1996.
29. Albert, A. and Serjeant, E.P., The Determination of Ionization Constants, 3rd ed., Chapman & Hall, New York, 1984.
30. Donovan, S.F. and Pescatore, M.C., Method for measuring the logarithm of octanol-water partition coefficient by using short octadecyl-poly(vinyl-alcohol) high performance liquid chromatography columns, J. Chromatogr. A, 952, 47, 2002.
31. Comer, J. and Box, K., High throughput measurement of drug pKa values for ADME screening, JALA, 8, 55, 2003.
32. Kansy, M., Senner, F., and Gubernator, K., Physicochemical high throughput screening, J. Med. Chem., 41, 1007, 1998.
33. Hwang, K.K., Martin, N.E., and Jiang, L., Permeation prediction of M100240 using the PAMPA, J. Pharm. Sci., 6, 315, 2003.
34. Artursson, P., Palm, K., and Luthman, K., Caco-2 monolayers in experimental and theoretical predictions of drug transport, Adv. Drug Delivery Rev., 46, 27, 2001.
35. Stoner, C.L., Cleton, A., Johnson, K., Oh, D-M., Hallak, H., Brodfuehrer, J., Surendran, N., and Han, H.K., Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery, Int. J. Pharm., 269, 241, 2004.
36. Ingels, F.M. and Augustijns, P.F., Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2, J. Pharm. Sci., 92, 1545, 2003.
37. Balbach, S. and Korn, C., Pharmaceutical evaluation of early development candidates-the 100 mg approach, Int. J. Pharm., 275, 1, 2004.
38. Yu, H.S. and Adedoyin, A., ADME-Tox in drug discovery: integration of experimental and computational technologies, Drug Discov. Today, 8, 852, 2003.
39. Berry, I.R. and Nash, R., Pharmaceutical Process Validation, Marcel Dekker, New York, 1993.
40. Avdeef, A., Physicochemical profiling, Curr. Top. Med. Chem., 1, 277, 2001.
41. Avdeef, A., Box, K.J., Comer, J.E.A., Gilges, M., Hibbert, C., Patterson, W., and Tam, K.Y., PHmetric log P 11. pKa determination of water-insoluble drugs in organic solvent-water mixtures, J. Pharm. Biomed. Anal, 20, 1999, 631.
42. Surakitbanharn, Y., McCandless, R., Krzyzaniak, J.F., Dannenfelser, R-M., and Yalkowsky, S.H., Self-association of dexverapamil in aqueous solution, J. Pharm. Sci., 84, 720, 1995.
43. Hansch, C. and Leo, A., Substituent Constants for Correlation Analysis in Chemistry and Biology, Wiley Interscience, New York, 1979.
44. Reynolds, D.W., Fachine, K.L., Mullaney, J.F., Alsante, K.M., Hatajik, T.D., and Moto, G.M., Available guidance and best practices for conducting forced degradation studies, Pharm. Technol., February, 48, 2002.
45. Carstensen, J.T. and Rhodes, C.T., Eds., Drug Stability: Principles and Practices, Marcel Dekker, New York, 2000.
46. Yoshioka, S. and Stella, V.J., Stability of Drugs and Dosage Forms, Kluwer Academic, New York, 2002.
47. Physician’s Desk Reference 2004.
48. Morris, K.R., Fakes, M.G., Thakur, A.B., Newman, A.W., Singh, A.K., Venit, J.J., Spagnuolo, C.J., and Serajuddin, A.T.M., An integrated approach to the selection of optimal salt form for a new drug candidate, Int. J. Pharm., 105, 209, 1994.
49. International Conference on Harmonization Q6A Guideline: Specifications for new drug substances and products: Chemical Substances, October 1999.
50. Morissette, S.L., Almarsson, O., Peterson, M.L., Remenar, J.F., Read, M.J., Lemmo, A.V., Ellis, S., Cima, M.J., and Gardner, C.R., High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids, Adv. Drug Delivery Rev., 56, 275, 2004.
51. Bauer, J., Spanton, S., Henry, R., Quick, J., Dziki, W., Porter, W., and Morris, J., Ritonavir: an extraordinary example of confirmation polymorphism, Pharm. Res., 18, 859, 2001.
52. Brittain, H.G., Polymorphism in Pharmaceutical Solids, 1st ed., Marcel Dekker, New York, 1999.
53. ICH Guidance for Industry Q1B, Photostability testing of new drug substances and products, November 1996.
54. Badawy, S.I., Williams, R.C., and Gilbert, D.L., Chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms, J. Pharm. Sci., 88, 428, 1999.
55. Serajuddin, A.T.M., Thakur, A.B., Ghoshal, R.N., Fakes, M.G., and Varia, S.A., Selection of solid dosage form composition through drug-excipient compatibility testing, J. Pharm. Sci., 88, 696, 1999.
56. Schmitt, E.A., Peck, K., Sun, Y., and Geoffroy, J-M., Rapid, practical and predictive excipient compatibility screening using isothermal microcalorimetry, Thermochim. Acta, 380, 175, 2001.
57. Monkhouse, D.C. and Maderich, A., Whither compatibility testing?, Drug Dev. Ind. Pharm., 15, 2115, 1989.
58. Crawley, P., Drug-excipient interactions, Pharm. Tech Eur., 13, 2001, 26.
59. Landin, M., Casalderrey, M., Martinez-Pacheco, R., Gómez-Amoza, J.L., Souto, C., Concheiro, A., and Rowe, R.C., Chemical stability of acetylsalicyclic acid in tablets prepared with different particle size fractions of a commercial brand of dicalcium phosphate dihydrate, Int. J. Pharm., 123, 143, 1995.
60. Irwin, W.J. and Iqbal, M., Solid-state stability: the effect of grinding solvated excipients, Int. J. Pharm., 75, 211, 1991.
61. Villalobos-Hernández, J.R. and Villafuerte-Robles, L., Effect of carrier excipient and processing on stability of indorenate hydrochloride/excipient mixtures, Pharm. Dev. Tech., 6, 551, 2001.
62. Rowe, R.C., Sheskey, P.J., and Weller, P.J., Handbook of Pharmaceutical Excipients, 4th ed., Pharmaceutical Press, London, 2003.
63. Hancock, B.C., Colvin, J.T., Mullarney, M.P., and Zinchuk, A.V., The relative densities of pharmaceutical powders, blends dry granulation, and immediate release tablets, Pharm. Technol., 4, 64, 2003.
64. Rowley, G., Quantifying electrostatic interactions in pharmaceutical powder systems, Int. J. Pharm., 227, 47, 2001.
65. Hiestand, E.N. and Smith, D.P., Three indexes for characterizing the tableting performance of materials, Adv. Ceramics, 9, 47, 1984.
66. Roberts, R.J. and Rowe, R.C., The compaction of pharmaceutical and other model materials - a pragmatic approach, Chem. Eng. Sci., 42, 903, 1987.
67. Amidon, G.L., Lennernas, H., Shah, V.P., and Crison, J.R., Theoretical basis for a biopharmaceutical drug classification: correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413, 1995.
68. FDA, Guidance for industry: Dissolution testing of immediate release solid oral dosage forms, 1997.
69. Curatolo, W., Physical chemical properties of oral drug candidates in the discovery and exploratory setting, Pharm. Sci. Tech. Today, 1, 387, 1998.
70. Agoram, B., Woltosz, W.S., and Bolger, M.B., Predicting the impact of physiological and biochemical processes on oral drug bioavailability, Adv. Drug Delivery Rev., 50, S41, 2001.
71. Kramer, S.F. and Flynn, G.L., Solubility of organic hydrochlorides, J. Pharm. Sci., 61, 1896, 1972.
72. Serajuddin, A.T.M. and Pudipeddi, M., Salt selection strategies, in Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Stahl, P.H. and Wermuth, C.G., Eds., Wiley-VCH, Weinheim, 2002, p. 135.
73. Johnson, K.C. and Swindell, A.C., Guidance in the setting of drug particle size specifications to minimize variability in absorption, Pharm. Res., 13, 1795, 1996.
74. Pudipeddi, M., Serajuddin, A.T.M., Grant, D.J.W., and Stahl, P.H., Solubility and dissolution of weak acids, bases, and salts, in Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Stahl, P.H. and Wermuth, C.G., Eds., Wiley-VCH, Weinheim, 2002, p. 19.
75. Dill, W.A., Kazenko, A., Wolf, L.M., and Glazko, A.J., Studies on 5,5'-diphenylhydantoin (Dilantin) in animals and man, J. Pharmacol. Exp. Ther., 118, 270, 1956.
76. Serajuddin, A.T.M., Sheen, P.C., Mufson, D., Bernstein, D.F., and Augustine, M.A., Preformulation study of a poorly water soluble drug, alpha-pentyl-3-(2-quinolinylmethoxy) benzenemethanol: selection of the base for dosage form design, J. Pharm. Sci., 75, 492, 1986.
77. Serajuddin, A.T.M., Sheen, P., Mufson, D., Bernstein, D.F., and Augustine, M.A., Physicochemical basis of increased bioavailability of a poorly water-soluble drug following oral administration as organic solutions, J. Pharm. Sci., 77, 325, 1988.
78. Washington, N., Washington, C., and Wilson, C.G., Physiological Pharmaceutics, 2nd ed., Taylor and Francis, New York, 2001, chap. 5.
79. Davis, S.S., Hardy, J.G., and Fara, J.W., Transit of pharmaceutical dosage forms through the small intestine, Gut, 27, 886, 1986.
80. Smith, C.G., Poutisiaka, J.W., and Schreiber, E.C., Problems in predicting drug effects across species lines, J. Int. Med. Res., 1, 489, 1973.
81. Chiou, W.L., Ma, C., Chung, S.M., Wu, T.C., and Jeong, H.Y., Similarity in the linear non-linear oral absorption of drugs between human and rat, Int. J. Clin. Pharmacol. Ther., 38, 532, 2000.
82. Chiou, W.L., Jeong, H.Y., Chung, S.M., and Wu, T.C., Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans, Pharm. Res., 17, 135, 2000.
83. Li, S., He, H., Parthiban, L., Yin, H., and Serajuddin, A.T.M., IV-IVC considerations in the development of immediate-release oral dosage form, J. Pharm. Sci., 94, 1396, 2005.
84. FDA, Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlation, 1997.
85. Dressman, J.B., Dissolution testing of immediate-release products and its application to forecasting in vivo performance, Oral Drug Absorption: Prediction and Assessment, Dressman, J.B. and Lennernas, H., Eds., Marcel Dekker, New York, 2000, p. 155.
86. Hariharan, M., Ganorkar, L.D., Amdion, G.E., Cavallo, A., Gatti, P., Hageman, M.J., Choo, I., Miller, J.L., and Shah, U.J., Reducing the time to develop and manufacture formulations for first oral dose in humans, Pharm. Technol., October, 68, 2003.
87. Sistla, A., Sunga, A., Phung, K., Iparkar, A., and Shenoy, N., Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials, Drug Dev. Ind. Pharm., 30, 19, 2004.
88. Aubry, A.F., Sebastian, D., Hobson, T., Xu, J.Q., Rabel, S., Xie, M., and Gray, V., In-use testing of extemporaneously prepared suspension of second generation non-nucleoside reversed transcriptase inhibitors in support of Phase I clinical studies, J. Pharm. Biomed. Anal., 23, 535, 2000.
89. Shah, V.P., Noory, A., Noory, C., McCullough, B., Clarke, S., Everett, R., Navkiasky, H., Srinivasan, B.N., Fortman, D., and Skelly, J.P., In vitro dissolution of sparingly water-soluble drug dosage forms, Int. J. Pharm., 125, 99, 1995.
90. Abrahamsson, B. and Ungell, A.L., Biopharmaceutical support in formulation development, in Pharmaceutical Preformulation and Formulation, Gibson, M., Ed., CRC Press, Boca Raton, FL.
91. Waterman, K.C., Adami, R.C., Alsante, K.M., Hong, J., Landis, M.S., Lombardo, F., and Roberts, C.J., Stabilization of pharmaceuticals to oxidative degradation, Pharm. Dev. Tech., 7, 1, 2002.
92. Al-Omari, M.M., Abelah, M.K., Badwan, A.A., and Aaber, A.M., Effect of drug matrix on the stability of enalapril maleate in tablet formulation, J. Pharm. Biomed. Anal., 25, 893, 2001.
93. Shek, E., Ghani, M., and Jones, R.E., Simplex search in optimization of a capsule formulation, J. Pharm. Sci., 69, 1135, 1980.
94. Bateman, S.D., Verlin, J., Russo, M., Guillot, M., and Laughlin, S.M., Development and validation of a capsule formulation knowledge-based system, Pharm. Technol., 20, 174, 1996.
95. Shiromani, P.K. and Clair, J., Statistical comparison of high shear vs. low shear granulation using a common formulation, Drug Dev. Ind. Pharm., 26, 357, 2000.
96. ICH Guidance for Industry Topic Q 1 A: Stability testing of New Drug Substances and Products, 2003.
97. Nash, R.A., Validation of pharmaceutical processes, in Encyclopedia of Pharmaceutical Technology, Swarbrick, J. and Boylan, J.C., Eds., Marcel Dekker, New York, 2002.
98. Pharmaceutical cGMPs for the 21st century: A risk based approach. US Food and Drug Administration, www.fda.gov/cder/gmp/index.htm
99. FDAGuidance to Industry: Bioavailability and bioequivalence studies for orally administered drug products - General considerations, 2002.
100. Cupissol, D., Bressolle, F., Adenis, L., Carmichael, J., and Romain, D., Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease, J. Pharm. Sci., 82, 1281, 1993.
101. Akers, M.J., Fites, A.L., and Robinson, R.L., Formulation design and development of parenteral suspensions, Bull. Parent Drug Assoc., 41, 88, 1987.
102. Broadhead, J., Parenteral dosage forms, in Pharmaceutical Preformulation and Formulation, Gibson, M., Ed., Interpharm/CRC Press, New York, 2004.
103. Akers, M.J., Parenteral Quality Control: Sterility, Pyrogen, Particulate, and Package Integrity Testing, Marcel Dekker, New York, 1994.
104. Sweetana, S. and Akers, M.J., Solubility principles and practices for parenteral drug dosage form development, J. Pharm. Sci. Technol., 50, 330, 1996.
105. Gupta, P.K., Patel, J.P., and Hahn, K.R., Evaluation of pain and irritation following local administration of parenteral formulations using the rat paw lick model, J. Pharm. Sci. Technol., 48, 159, 1994.
106. Nema, S., Washkuhn, R.J., and Brendel, R.J., Excipients and their use in injectable products, J. Pharm. Sci. Technol., 51, 166, 1997.
107. Strickley, R.J., Parenteral formulation of small molecules therapeutics marketed in the United States-Part III, PDA J. Pharm. Sci. Tech., 54, 152, 2000.
108. Tang, X.L., Pikal, M.J., and Taylor, L.S., Design of freeze-drying processes for pharmaceuticals:practical advice, Pharm. Res., 21, 191, 2004.
109. Puri, N., Pejaver, S.K., Parnajpe, P., and Sinko, P.J., Bioavailability of parenteral dosage forms, US Pharmacist, 26, HS41-HS53, HS55-HS56, 2001.
110. Suarez, S. and Hickey, A.J., Drug properties affecting aerosol behavior, Respir. Care, 45, 652, 2000.
111. Poochikian, G. and Bertha, C.M., Regulatory view on current issues pertaining to inhalation drug products, Respiratory Drug Delivery VIII Conference, Vol. 1, 2000, pp. 159-164 [www.rddonline.com].
112. Hickey, A.J. and Martonen, T.B., Behavior of hygroscopic pharmaceutical aerosols and the influence of hydrophobic additives, Pharm. Res., 10, 1, 1993.
113. Hodges, C.C., Lloyd, P.M., Mufson, D., Rogers, D.D., and Wensley, M.J., Delivery of Aerosols Containing Small Particles through an Inhalation Route, US 6,682,716, January 27, 2004.
114. Rabinowitz, J.D., Wensley, M., Lloyd, P., Myers, D., Shen, W., Lu, A., Hodges, C., Hale, R., Mufson, D., and Zaffaroni, A., Fast onset medications through thermally generated aerosols, J. Pharmacol. Exp. Ther., 309, 769, 2004.
115. Amiel, S.A. and Alberti, K.G., Inhaled insulin, BMJ, 328, 1215, 2004.
116. Zaffaroni, A., Therapeutic systems: the key to rational drug therapy, Drug Metab. Rev., 8, 191, 1978.
117. Swintosky, J.V., Personal adventures in biopharmaceutical research during the 1953-1984 years, Drug Intell. Clin. Pharm., 19, 265, 1985.
118. Allen, T.M. and Cullis, P.R., Drug delivery systems: entering the mainstream, Science, 303, 1818, 2004.
119. Novel Drug Delivery Systems (NDDS) Reports, Technology Catalysts International, Falls Church, VA, 2002.
120. Hastings, M.S., Li, S.K., Miller, D.J., Bernstein, P.S., and Mufson, D., Visulex™: advancing iontophoresis for effective noninvasive back-of-the-eye therapeutics, Drug Delivery Technol., 4, 53, 2004.
121. Horspool, K.A. and Lipinski, C.A., Advancing new drug delivery concepts to gain the lead, Drug Delivery Technol., 3, 34, 2003.
122. Meinzer, A., Mueller, E., and Vonderscher, J., Microemulsion - A suitable galenical approach for the absorption enhancement of low soluble compounds?, in Absorption of Micellar Systems:Bulletin Technique Gattefossé, Barthelemy, P., Ed., Gattefossé S.A., Saint-Priest, France, 1995, p. 21.
123. McClellan, M.B., Speech before PhRMA, March 28, 2003 (available at www.fda.gov).